Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards to Eric J Daniels, M.D., who joined as Chief Development Officer on April 20, 2026. The awards include 20,000 stock options and 20,000 restricted stock units (RSUs), approved under Nasdaq Rule 5635(c)(4).

Options have a 10-year term with an exercise price of $7.30 (fair market value at grant). Options vest over four years; RSUs vest over three years, each subject to continued service.

Positive

• Granted 20,000 stock options and 20,000 RSUs to new Chief Development Officer
• Options carry a 10-year term with a $7.30 exercise price
• Options vest over four years; RSUs vest over three years, supporting retention
• Awards approved under Nasdaq Rule 5635(c)(4), meeting listing requirements

Negative

• None.

News Market Reaction – PSTV

-4.46%

9 alerts

-4.46% News Effect

+6.4% Peak Tracked

-9.0% Trough Tracked

-$3M Valuation Impact

$54.90M Market Cap

0.3x Rel. Volume

On the day this news was published, PSTV declined 4.46%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.4% during that session. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $54.90M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Stock options granted: 20,000 options RSUs granted: 20,000 RSUs Option exercise price: $7.30 +5 more

8 metrics

Stock options granted 20,000 options Inducement award under 2015 New Employee Incentive Plan

RSUs granted 20,000 RSUs Inducement award to new Chief Development Officer

Option exercise price $7.30 Equal to fair market value on April 20, 2026

Option term 10 years Tenor of inducement stock options

Initial option vesting 25% Vests on first anniversary of April 20, 2026

Ongoing option vesting 1/36 per month Monthly vesting following first-year cliff, over remaining term

Initial RSU vesting 1/3 of RSUs Vests first of quarter after first anniversary

Remaining RSU vesting Over 8 quarters Ratable vesting of remaining RSUs over next eight quarters

Market Reality Check

Price: $5.60 Vol: Volume 425,899 is below t...

low vol

$5.60 Last Close

Volume Volume 425,899 is below the 20-day average of 647,502, suggesting muted trading interest ahead of this announcement. low

Technical Shares at $7.62 trade below the 200-day MA of $11.3 and remain 75.02% under the 52-week high of $30.5.

Peers on Argus

PSTV gained 3.16% while peers showed mixed but generally modest moves: RADX +0.2...

1 Up

PSTV gained 3.16% while peers showed mixed but generally modest moves: RADX +0.22%, BCAB +2.82%, BRNS +2.8%, RNXT -1.7%, VRCA +0.85%. Momentum scanner only flagged one peer, supporting a stock-specific move tied to company developments rather than a broad sector rotation.

Historical Context

5 past events · Latest: Apr 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 21	Nasdaq compliance	Positive	-2.2%	Regained compliance with Nasdaq minimum bid price listing requirement.
Apr 15	Executive appointment	Positive	+4.0%	Appointed VP of Value Strategy & HEOR with related inducement equity grants.
Apr 09	Chief Development Officer hire	Positive	+23.7%	Named Eric J. Daniels as CDO to advance CNS radiopharmaceutical pipeline.
Apr 08	Orphan designation	Positive	+8.6%	FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas.
Apr 07	Reimbursement catalyst	Positive	-12.3%	Received AMA PLA CPT code for CNSide CSF tumor cell enumeration test.

Pattern Detected

Recent PSTV news has generally been positive, with three of five events seeing aligned positive price reactions. However, two constructive operational or regulatory updates were followed by negative moves, indicating occasional sell-the-news or profit-taking behavior even on favorable announcements.

Recent Company History

Over the past weeks, Plus Therapeutics has reported several regulatory and corporate milestones. Regaining Nasdaq minimum bid compliance on Apr 21 followed a 1-for-25 reverse split and saw a -2.19% reaction. Senior hires on Apr 9 and Apr 15 drew stronger gains of 23.66% and 4.05%. Orphan Drug Designation for REYOBIQ on Apr 8 produced an 8.56% move, while an AMA PLA code announcement on Apr 7 coincided with a -12.31% decline. Today’s inducement awards tie directly to the previously announced CDO hire.

Market Pulse Summary

This announcement details equity inducement awards tied to the new Chief Development Officer, includ...

Analysis

This announcement details equity inducement awards tied to the new Chief Development Officer, including 20,000 options at $7.30 and 20,000 RSUs with multi-year vesting. It follows recent milestones such as FDA Orphan Drug Designation and Nasdaq compliance. Investors may track how leadership changes translate into pipeline progress and whether ongoing board- and plan-related governance actions support longer-term value creation.

Key Terms

restricted stock units, rsus, exercise price, nasdaq rule 5635(c)(4), +2 more

6 terms

restricted stock units financial

"The inducement awards consist of options to purchase 20,000 shares... and 20,000 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"Each RSU represents a contingent right to receive one share of the Company’s common stock"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

exercise price financial

"The options have a 10-year term and an exercise price equal to $7.30"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

nasdaq rule 5635(c)(4) regulatory

"approved by the Compensation Committee... as required by Nasdaq Rule 5635(c)(4)"

NASDAQ Rule 5635(c)(4) is a listing standard that requires a company to obtain shareholder approval before issuing a substantial number of new shares or convertible securities in certain financing or insider-related transactions that would materially dilute existing holders. It matters to investors because the vote gives shareholders a check on deals that could significantly change ownership stakes or voting power—like a homeowners’ association approving a major renovation that affects the whole neighborhood’s value.

equity awards financial

"2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

inducement awards financial

"announces that it has granted inducement awards to Eric J Daniels, M.D."

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

AI-generated analysis. Not financial advice.

HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026.

The awards were granted on April 20, 2026 under the Company’s 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common stock and 20,000 restricted stock units (“RSUs”).

The options have a 10-year term and an exercise price equal to $7.30, the fair market value of the Company’s common stock on the date of grant. The options vest over a four-year period, with 25% of the shares subject to the options vesting on the first anniversary of the vesting commencement date of April 20, 2026, and 1/36^th vesting on each monthly anniversary thereafter, subject to Dr. Daniels’ continued service with the Company through each applicable vesting date.

Each RSU represents a contingent right to receive one share of the Company’s common stock and there is no exercise price associated with the RSUs granted thereunder. The RSUs vest over a three-year period, with 1/3 vesting on the first of the quarter immediately following the first anniversary of the grant date, and the remaining RSUs vesting ratably over the next 8 quarters, subject to Dr. Daniels’ continued service with the Company through each applicable vesting date.

The awards were approved by the Compensation Committee of the Company’s board of directors, as required by Nasdaq Rule 5635(c)(4), and were granted as an inducement material to Dr. Daniels entering into employment with the Company in accordance with Nasdaq Rule 5635(c)(4).

About Plus Therapeutics

Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products.

Investor Contact
CORE IR
investor@plustherapeutics.com

FAQ

What equity awards did Plus Therapeutics (PSTV) grant to its new CDO on April 20, 2026?

The company granted 20,000 options and 20,000 RSUs to the new CDO. According to the company, options have a 10-year term and an exercise price of $7.30 set at grant.

How do the options and RSUs granted by PSTV vest for the new Chief Development Officer?

Options vest over a four-year schedule with 25% after one year then monthly vesting. According to the company, RSUs vest over three years across quarterly installments.

Does Plus Therapeutics (PSTV) state the exercise price for the options granted on April 20, 2026?

Yes. The exercise price is $7.30, equal to the fair market value on the grant date. According to the company, that price applies to the full 10-year option term.

Were the inducement awards to PSTV's new CDO approved in line with Nasdaq rules?

Yes. The awards were approved by the compensation committee as required under Nasdaq Rule 5635(c)(4). According to the company, the grants were made as an inducement to join.

How many shares could be issued by PSTV if all granted awards to the new CDO vest and options are exercised?

Up to 40,000 shares could be issued: 20,000 from RSUs and 20,000 from exercised options. According to the company, issuance is subject to vesting and exercise conditions.